KalVista Pharmaceuticals
- Country
- πΊπΈUnited States
- Ownership
- Public
- Established
- 2011-01-01
- Employees
- 150
- Market Cap
- $546.2M
- Website
- http://www.kalvista.com
- Introduction
KalVista Pharmaceuticals, Inc. is a clinical stage pharmaceutical company, which engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet need. Its product candidates are inhibitors of plasma kallikrein being developed for two indications: Sebetralstat for HAE and Factor XIIa. The company was founded by T. Andrew Crockett, Edward P. Feener, and Lloyd Paul Aiello on March 26, 2004 and is headquartered in Cambridge, MA.
A Study Observing US Patients With HAE Type I or II Who Take Icatibant to Treat HAE Attacks
- Conditions
- Hereditary Angioedema
- First Posted Date
- 2025-06-06
- Last Posted Date
- 2025-06-06
- Lead Sponsor
- KalVista Pharmaceuticals, Ltd.
- Target Recruit Count
- 50
- Registration Number
- NCT07009262
- Locations
- πΊπΈ
KalVista Investigative Site, Fairfax, Virginia, United States
Treatment of Angioedema Attacks in Adolescent and Adult Patients 12 Years and Older With HAE Type I or II With Sebetralstat
- Conditions
- Hereditary Angioedema
- First Posted Date
- 2024-10-08
- Last Posted Date
- 2025-01-20
- Lead Sponsor
- KalVista Pharmaceuticals, Ltd.
- Registration Number
- NCT06628713
- Locations
- πΊπΈ
KalVista Investigative Site, Scottsdale, Arizona, United States
Open-Label Safety, PK, and Efficacy Trial of Sebetralstat (KVD900) in Pediatric Patients (Ages 2-11) With HAE Type I or II
- Conditions
- Hereditary Angioedema
- Interventions
- Drug: KVD900 75 mgDrug: KVD900 150 mgDrug: KVD900 300 mg
- First Posted Date
- 2024-06-20
- Last Posted Date
- 2025-06-10
- Lead Sponsor
- KalVista Pharmaceuticals, Ltd.
- Target Recruit Count
- 36
- Registration Number
- NCT06467084
- Locations
- πΊπΈ
KalVista Investigative Site, Wheaton, Maryland, United States
π―π΅KalVista Investigative Site, Tokyo, Japan
PK Subtrial in Adolescent Patients With HAE Type I or II Participating in the KVD900-302 Trial
- Conditions
- Hereditary Angioedema
- Interventions
- Drug: KVD900 600 mg
- First Posted Date
- 2022-08-23
- Last Posted Date
- 2025-01-08
- Lead Sponsor
- KalVista Pharmaceuticals, Ltd.
- Target Recruit Count
- 12
- Registration Number
- NCT05511922
- Locations
- π¬π§
KalVista Investigative Site, London, United Kingdom
πΊπΈKalvista Investigative Site, Hershey, Pennsylvania, United States
π¬π§KalVista Investgative Site, Frimley, United Kingdom
An Open-label Extension Trial to Evaluate the Long-term Safety of KVD900 (Sebetralstat) for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema (HAE)
- Conditions
- Hereditary Angioedema
- Interventions
- Drug: KVD900 600 mgDrug: KVD900 300 mg
- First Posted Date
- 2022-08-18
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- KalVista Pharmaceuticals, Ltd.
- Target Recruit Count
- 145
- Registration Number
- NCT05505916
- Locations
- π¬π§
KalVista Investigative Site, London, United Kingdom
π―π΅KalVista Investgative Site, Tokyo, Japan
πΏπ¦Kalvista Investigative Site, Cape Town, South Africa
A Phase III, Crossover Trial Evaluating the Efficacy and Safety of KVD900 (Sebetralstat) for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema (HAE)
- Conditions
- Hereditary Angioedema
- Interventions
- Drug: KVD900 600 mgDrug: KVD900 300 mgDrug: Placebo
- First Posted Date
- 2022-03-02
- Last Posted Date
- 2025-05-02
- Lead Sponsor
- KalVista Pharmaceuticals, Ltd.
- Target Recruit Count
- 136
- Registration Number
- NCT05259917
- Locations
- π¬π§
KalVista Investigative Site, London, United Kingdom
π¬π·Kalvista Investigative Site, Athens, Greece
π―π΅KalVista Investgative Site, Chiba-shi, Japan
A Single and Multiple Doses Safety, Tolerability, Pharmacokinetics and Food Effect Study of KVD824 in Healthy Volunteers
- First Posted Date
- 2022-01-05
- Last Posted Date
- 2022-02-17
- Lead Sponsor
- KalVista Pharmaceuticals, Ltd.
- Target Recruit Count
- 108
- Registration Number
- NCT05178355
- Locations
- π¬π§
KalVista Investigative Site, Merthyr Tydfil, United Kingdom
Phase 1 Crossover Study in Healthy Subjects to Evaluate the PK Profile of KVD824 Following Single and Multiple Doses of Modified Release (MR) Formulations
- Conditions
- Hereditary Angioedema
- Interventions
- Drug: KVD824 Prototype 1 modified-release tabletDrug: KVD824 Prototype 2 modified-release tabletDrug: Placebo to KVD824 Prototype 1Drug: KVD824 Immediate-Release CapsuleDrug: KVD824 Prototype 3 modified-release tablet
- First Posted Date
- 2021-11-12
- Last Posted Date
- 2021-11-12
- Lead Sponsor
- KalVista Pharmaceuticals, Ltd.
- Target Recruit Count
- 37
- Registration Number
- NCT05118958
- Locations
- π¬π§
KalVista Investigative Site, Nottingham, United Kingdom
A Trial to Evaluate the Efficacy and Safety of Different Doses of KVD824 for Prophylactic Treatment of HAE Type I or II
- Conditions
- Angioedema, Hereditary, Types I and II
- Interventions
- Drug: Placebo to KVD824
- First Posted Date
- 2021-09-24
- Last Posted Date
- 2023-10-10
- Lead Sponsor
- KalVista Pharmaceuticals, Ltd.
- Target Recruit Count
- 33
- Registration Number
- NCT05055258
- Locations
- π¬π§
KalVista Investigative Site, Newcastle Upon Tyne, United Kingdom
A Single Dose Safety, Tolerability, Pharmacokinetic and Food Effect Study of KVD900 (Sebetralstat) in Healthy Volunteers
- First Posted Date
- 2020-04-16
- Last Posted Date
- 2025-04-29
- Lead Sponsor
- KalVista Pharmaceuticals, Ltd.
- Target Recruit Count
- 84
- Registration Number
- NCT04349800
- Locations
- π¬π§
KalVista Investigative Site, Wales, United Kingdom